Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010

Table 1 Summary of the terms used singly or in combination for evidence acquisition

Primary MeSH terms	Secondary MeSH terms (epidemiology, diagnosis)	Secondary MeSH terms (treatment, palliation)
Pancreatic neoplasm(s)	Epidemiology	Pancreaticoduodenectomy
Adenocarcinoma(s)	Classification	Resection
Carcinoma(s)	Diagnosis	Therapeutic(s)
Pancreatic diseases	Differential diagnosis	Treatment outcome(s)
Pancreas	Risk factor(s)	Surgery
Carcinoma, pancreatic ductal	Diagnostic imaging	Surgical procedures
Pancreatic duct(s)	Magnetic resonance imaging	Clinical trial(s)
Humans	Endosonography	Controlled clinical trial(s)
Adult	Ultrasonography	Randomized controlled trial(s)
	Emission computed tomography	Clinical trial (phase I)
	Radionuclide imaging	Clinical trial (phase II)
	Positron emission tomography	Clinical trial (phase III)
	Tomography	Clinical trial (phase IV)
	X-ray computed	Drug therapy
	Biopsy (fine needle)	Chemotherapy
	Biopsy (needle)	Neoadjuvant therapy
	Cytology	Adjuvant
	Cytodiagnosis	Antineoplastic combined chemotherapy protocols
	Tumor markers (biological) antigen(s)	Antineoplastic agent(s)
	Carcinoembryonic antigen	Antimetabolites, antineoplastic
	Ca 19-9 antigen	Combined modality therapeutic antineoplastic
	Ca 125 antigen	Combined chemotherapy protocols neoadjuvant
	Antigens, tumor-associated, carbohydrate	Therapy
	Endoscopic retrograde cholangiopancreatography	Radiotherapy
	Computed assisted image processing	Drainage
	Sensitivity and specificity	Cholestasis
	Endoscopy	Obstructive jaundice
		Celiac plexus
		Autonomic nerve block
		Nerve block
		Ethanol
		Injections, intralesional
		Cisplatin
		Deoxycytidine
		Epidermal growth factor
		Fluorouracil
		Endostatin
		Biological products
		Neoplasm proteins
		Immunotherapy
		Antibodies, monoclonal